NYLIM
HZNP

New York Life Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

New York Life Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-268,034
Closed -$31M – 1374
2023
Q3 		$31M Buy
268,034
+9,201
+4% +$989K 0.34% 55
2023
Q2 		$26.6M Buy
258,833
+4,351
+2% +$459K 0.28% 69
2023
Q1 		$27.8M Buy
254,482
+249,963
+5,531% +$27.6M 0.31% 62
2022
Q4 		$514K Sell
4,519
-336
-7% -$27.9K 0.01% 908
2022
Q3 		$300K Sell
4,855
-56
-1% -$3.91K ﹤0.01% 1106
2022
Q2 		$392K Buy
+4,911
New +$465K ﹤0.01% 989
2015
Q4 		– Sell
-11,086
Closed -$220K – 234
2015
Q3 		$220K Sell
11,086
-57
-0.5% -$1.8K 0.02% 192
2015
Q2 		$387K Buy
+11,143
New +$340K 0.04% 123

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

New York Life Investment Management's HZNP Position: Q4 2023 in Review

New York Life Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 268,034 shares — an estimated $31M sold.

New York Life Investment Management first reported a position in HZNP in Q2 2015 and held it in 8 quarters. The position peaked at $31M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • New York Life Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • New York Life Investment Management sold 268,034 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $31M.
  • New York Life Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 8 quarters.
  • New York Life Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $31M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on New York Life Investment Management's 13F filing for Q4 2023, filed 6 Feb 2024.